Tsukasa Matsubara
Overview
Explore the profile of Tsukasa Matsubara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sasa N, Kojima S, Koide R, Hasegawa T, Namkoong H, Hirota T, et al.
Nat Genet
. 2025 Jan;
57(1):65-79.
PMID: 39753770
Aberrant immune responses to viral pathogens contribute to pathogenesis, but our understanding of pathological immune responses caused by viruses within the human virome, especially at a population scale, remains limited....
2.
Takanashi S, Ohmura K, Misaki K, Ihata A, Matsui T, Tohma S, et al.
BMJ Open
. 2024 Nov;
14(11):e090668.
PMID: 39551586
Introduction: Janus kinase (JAK) inhibitors are an important therapeutic option in the treatment of rheumatoid arthritis, but increase the risk of developing herpes zoster. Although a dry recombinant zoster vaccine...
3.
Tanaka Y, Matsubara T, Atsumi T, Amano K, Ishiguro N, Hirata S, et al.
Mod Rheumatol
. 2024 Nov;
PMID: 39506562
Objectives: To describe safety and efficacy of filgotinib 200 or 100 mg (FIL200/FIL100) in Japanese patients with rheumatoid arthritis in a long-term extension (LTE; NCT03025308). Methods: Patients who completed any...
4.
Anjiki K, Hayashi S, Ikuta K, Suda Y, Kamenaga T, Tsubosaka M, et al.
Clin Rheumatol
. 2024 Sep;
43(11):3525-3536.
PMID: 39302595
Introduction/objectives: JAK/STAT signaling inhibition exerts therapeutic effects on angiogenesis in rheumatoid arthritis (RA). However, whether the inhibitory effect differs among JAK inhibitors because of differing selectivity is unknown. Therefore, we...
5.
Saraux A, Mota L, Dixit S, Gibofsky A, Matsubara T, Mulvey A, et al.
Rheumatol Ther
. 2024 Jan;
11(2):257-268.
PMID: 38217796
Introduction: The global coronavirus 2019 (COVID-19) pandemic created many challenges in healthcare provision. This study aimed to evaluate the global impact of the COVID-19 pandemic on people living with rheumatoid...
6.
Matsubara T, Katayama K, Sagawa A, Yoshida M, Mitsuka T, Hashimoto K, et al.
Mod Rheumatol
. 2023 Mar;
34(2):307-312.
PMID: 36943727
Objectives: To assess the usefulness and onset of nocebo effects after switching from the original etanercept (ETN) to a biosimilar (BS) in routine clinical practice at rheumatology clinics in Japan...
7.
Hayashi S, Matsubara T, Fukuda K, Maeda T, Funahashi K, Hashimoto M, et al.
Rheumatol Adv Pract
. 2022 Nov;
6(3):rkac088.
PMID: 36382269
Objective: Genetic polymorphisms might serve as useful prognostic markers for the timely diagnosis of RA. The purpose of this study was to identify genomic factors predictive of the occurrence of...
8.
Hayashi S, Matsubara T, Maeda T, Fukuda K, Funahashi K, Hashimoto M, et al.
Sci Rep
. 2022 Oct;
12(1):17524.
PMID: 36266430
We compared the efficacy of tocilizumab and etanercept in inhibiting radiographic progression of joint destruction in rheumatoid arthritis. Overall, 187 patients treated with etanercept or tocilizumab were selected. To adjust...
9.
Kikuchi K, Fukuda K, Hayashi S, Maeda T, Takashima Y, Fujita M, et al.
Mod Rheumatol Case Rep
. 2022 Oct;
7(1):320-323.
PMID: 36214605
Hepatitis B virus (HBV) infection can cause arthritis, but it is rarely reported. In the current report, we present a case of chronic polyarthritis in a patient with untreated HBV...
10.
Combe B, Besuyen R, Gomez-Centeno A, Matsubara T, Sancho Jimenez J, Yin Z, et al.
Rheumatol Ther
. 2022 Oct;
10(1):35-51.
PMID: 36205910
Introduction: Global clinical trials in rheumatoid arthritis (RA) often do not recruit enough patients from diverse racial and ethnic backgrounds to identify any potential differences in treatment outcome across such...